Xeris Biopharma Holdings Inc

Research Xeris Biopharma Holdings Inc (XERS) on Bullrun: valuation model: 67.5% overvalued, market cap USD 1.34B, P/E 118.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerXERS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Valuation signal67.5% overvalued
• Market capUSD 1.34B
• P/E118.2
• Financial periodFY2025
• RevenueUSD 291.85M
• Revenue growth43.7%
• Net incomeUSD 554.00K

Valuation Snapshot

Bullrun's latest valuation model marks Xeris Biopharma Holdings Inc as 67.5% overvalued; latest market cap is USD 1.34B; P/E is 118.2.

About Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis;

Frequently asked questions

Is Xeris Biopharma Holdings Inc overvalued or undervalued?

Bullrun's valuation model currently marks Xeris Biopharma Holdings Inc as 67.5% overvalued.

What is Xeris Biopharma Holdings Inc's market cap?

Xeris Biopharma Holdings Inc's market capitalization is USD 1.34B.

What is Xeris Biopharma Holdings Inc's P/E ratio?

Xeris Biopharma Holdings Inc's price-to-earnings (P/E) ratio is 118.2.

What does Xeris Biopharma Holdings Inc do?

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.